Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.

导出 LinkOut

翻译打印收藏纠错

作者： Alexandr,Poprach ^[1] ; Zbynek,Bortlicek ^[2] ; Bohuslav,Melichar ^[3] ; Radek,Lakomy ^[1] ; Marek,Svoboda ^[1] ; Igor,Kiss ^[1] ; Milada,Zemanova ^[4] ; Ondrej,Fiala ^[5] ; Katerina,Kubackova ^[6] ; Oldrich,Coufal ^[1] ; Tomas,Pavlik ^[2] ; Ladislav,Dusek ^[2] ; Rostislav,Vyzula ^[1] ; Tomas,Buchler ^[7]

作者单位： Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Zluty kopec 7, 656 53 Brno, Czech Republic. ^[1] Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 126/3, 625 00 Brno, Czech Republic. ^[2] Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic. ^[3] Department of Oncology, General University Hospital and Charles University First Faculty of Medicine, U Nemocnice 499/2, 128 08 Prague, Czech Republic. ^[4] Department of Oncology, University Hospital, Svobody 80, 304 60 Pilsen, Czech Republic. ^[5] Department of Oncology, Motol University Hospital and Charles University Second Faculty of Medicine,V uvalu 84/1, 150 00 Prague, Czech Republic. ^[6] Department of Oncology and First Faculty of Medicine, Thomayer Hospital and Charles University, Videnska 800, 140 59 Prague, Czech Republic. Electronic address: tomas.buchler@ftn.cz. ^[7]

关键词 Renal cell carcinoma Renal insufficiency Sunitinib Survival Treatment duration